Diplomatic Trade Acquires Major Stake in Turkish Pharmaceutical Company, Targets $300M IPO
Diplomatic Trade Ltd and its investment arm have secured a 49% equity position in a Turkish pharmaceutical company, with plans to launch a bio-manufacturing facility in the UAE and pursue a potential $300 million IPO in late 2025.
Diplomatic Trade Ltd has completed a strategic investment in Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S., a prominent Turkish pharmaceutical manufacturer, marking a significant expansion in the Middle Eastern healthcare sector. The company acquired a controlling 49% equity stake, positioning itself to transform pharmaceutical infrastructure across the MENA region.
The investment includes ambitious plans to establish a cutting-edge bio-manufacturing facility in the UAE by the third quarter of 2025. This facility will specialize in biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals, targeting growing healthcare demands in Gulf states and North Africa. The facility will incorporate advanced technologies, including AI-driven quality control and biocompatible packaging, adhering to EU-GMP standards.
Financial backing comes from Morgan Brookshire LLC, a U.S.-based private family office, underscoring the transatlantic commitment to developing pharmaceutical infrastructure in the Gulf region. The strategic partnership aims to create a comprehensive platform for pharmaceutical innovation and market expansion.
The joint venture is targeting an initial public offering on a leading UAE stock exchange in the fourth quarter of 2025, with early projections estimating a potential valuation of $300 million. This anticipated IPO represents a significant milestone in regional healthcare investment and demonstrates the growing sophistication of emerging market pharmaceutical ecosystems.
By bridging biotech innovation, investment banking, and pharmaceutical manufacturing, this venture signals a transformative approach to healthcare infrastructure development. The strategic investment highlights the increasing importance of cross-border collaborations in advancing medical technologies and supply chain capabilities in frontier markets.